TIVIC HEALTH SY.DL -,0001 Aktie

Tivic Health announced in its Q4 2025 earnings call a strategic realignment from consumer goods to biopharma, concentrating on the TLR5 immunotherapy platform—most notably the drug candidate Entolimod for oncological supportive therapies and biodefense. The company increased cash reserves to $12.6 million through acquisitions and bought, among others, Velocity Bioworks to bolster production capacity. Operating expenses rose sharply (+75.6% to $7.9 million), and the stock fell 3.92% premarket to $0.98. Tivic plans physician-initiated studies in 2025 and validation of GMP-compliant manufacturing but sees risks from higher funding needs and the loss of short-term consumer revenues. » More on de.investing.com

Tivic Health Systems is making a strategic shift from consumer-health products to biopharmaceuticals, focusing on immunological therapeutics and the TLR5 mechanism of action. In Q3 2025 revenue rose to $146,000, but nine‑month revenue fell to $302,000 and the net loss widened to $2.6 million. The stock fell 5.29% in after‑hours trading to $1.97; the company is preparing a biologics license application and plans Phase II studies as well as talks with BARDA. » More on de.investing.com

Tivic Health has filed two patent applications with the US Patent Office: one covering new uses of its TLR5 agonists Entolimod and Entolasta as adjuvants to enhance cell‑based immunotherapies for advanced cancers, and another for a non‑invasive vagus nerve stimulation system. The company says expanding its IP portfolio should create partnership opportunities and market potential for its dual bio and bioelectronic platform. At the same time, Tivic is executing a strategic shift toward biopharmaceutical therapies after a revenue decline in Q2 2025 and is coordinating regulatory steps for Entolimod with the FDA; talks with US authorities on radiation protection are also underway. » More on de.investing.com